Table 3.

Effects of tirzepatide on circulatory pressure–volume characteristics, inflammation and kidney function

Variable and duration of treatment	Change with tirzepatide from baseline	Change with placebo from baseline	ETD	95% CI	P
Systolic BP (mmHg)
12 weeks	−5.5	0.9	−6.4	−8.4 to −4.4	<0.001
24 weeks	−6.6	−0.3	−6.4	−8.3 to −4.5	<0.001
52 weeks	−4.6	0.1	−4.7	−6.8 to −2.5	<0.001
Diastolic BP (mmHg)
12 weeks	−1.1	−0.5	−0.7	−1.9 to −0.6	0.313
24 weeks	−1.7	−0.5	−1.3	−2.5 to 0.0	0.054
52 weeks	−1.2	−0.3	−0.9	−2.3 to 0.5	0.189
Pulse pressure (mmHg)
12 weeks	−4.4	1.4	−5.8	−7.4 to −4.1	<0.001
24 weeks	−4.9	0.3	−5.2	−6.8 to −3.7	<0.001
52 weeks	−3.5	0.4	−3.9	−5.6 to −2.2	<0.001
Estimated BV (l)
12 weeks	−0.27	−0.04	−0.23	−0.26 to −0.21	<0.001
24 weeks	−0.49	−0.07	−0.42	−0.45 to −0.38	<0.001
52 weeks	−0.68	−0.11	−0.58	−0.63 to −0.52	<0.001
Estimated PV (l)
12 weeks	−0.17	−0.03	−0.13	−0.16 to −0.11	<0.001
24 weeks	−0.27	−0.04	−0.23	−0.26 to −0.19	<0.001
52 weeks	−0.39	−0.08	−0.32	−0.36 to −0.27	<0.001
High-sensitivity CRP (% change from baseline)
12 weeks	−4.7	1.9	−6.5	−18.0 to 6.7	0.318
24 weeks	−21.5	−6.7	−15.9	−26.4 to −4.0	0.010
52 weeks	−39.8	−4.1	−37.2	−45.7 to −27.3	<0.001
eGFR (ml min−1 1.73 m−2)
12 weeks	−0.6	0.5	−1.1	−2.7 to 0.4	0.148
24 weeks	0.3	0.1	0.2	−1.4 to 1.8	0.818
52 weeks	2.6	−0.3	2.9	0.9 to 4.9	0.004
UACR (% change from baseline)
24 weeks	−26.4	−1.9	−25.0	−35.5 to −12.7	<0.001
52 weeks	−14.7	0.4	−15.1	−28.0 to 0.1	0.051
NT-proBNP level (% change from baseline)
12 weeks	−8.9	2.0	−10.8	−19.1 to −1.5	0.024
24 weeks	−10.2	−0.6	−9.7	−18.9 to 0.5	0.063
52 weeks	−7.2	3.7	−10.5	−20.7 to 1.0	0.072
Troponin T level (% change from baseline)
12 weeks	−1.3	−0.8	−0.6	−7.5 to 7.0	0.881
24 weeks	−8.6	1.4	−9.8	−16.0 to −3.3	0.004
52 weeks	−9.6	0.9	−10.4	−16.7 to −3.6	0.003

P values are two-sided for each time point comparison based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m⁻²), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.